Results 1 to 10 of about 334,749 (357)
Trends in Pharmacological Sciences, 1998 1993 represents the 100th anniversary of William Coley's first report of tumor regressions induced by immune system activation in response to bacterial toxins. While many subsequent cancer vaccine trials have yielded tantalizing results, active immunotherapy has not yet become an established modality of cancer therapy.
Drew M. Pardoll
openalex +5 more sources
Hematology/Oncology Clinics of North America, 2001 Attempts to generate an anticancer immune response in vivo in patients with cancer have taken several forms. Although to date there have been relatively few published studies describing the effects of the approach in hematologic malignancy, that circumstance is expected to change rapidly during the next few years. In solid tumors, it is not known which,
Raphaël F. Rousseau +3 more
+7 more sources
Cancer Cell, 2022 Given the renewed interest in vaccine development sparked by the COVID-19 pandemic, we are revisiting the current state of vaccine development for cancer prevention and treatment. Experts discuss different vaccine types, their antigens and modes of action, and where we stand on their clinical development, plus the challenges we need to overcome for ...
Schiller, John T +13 more
openaire +3 more sources
Cross-protective antibodies against common endemic respiratory viruses
Nature Communications, 2023 Respiratory syncytial virus (RSV), human metapneumovirus (HMPV), and human parainfluenza virus types one (HPIV1) and three (HPIV3) can cause severe disease and death in immunocompromised patients, the elderly, and those with underlying lung disease.
Madelyn Cabán +6 more
doaj +1 more source
Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans
npj Vaccines, 2021 We studied mucosal immune responses in six HIV-1 vaccine trials investigating different envelope (Env)-containing immunogens. Regimens were classified into four categories: DNA/vector, DNA/vector plus protein, protein alone, and vector alone. We measured
Kelly E. Seaton +29 more
doaj +1 more source
Anti-tumor activity of a T-helper 1 multiantigen vaccine in a murine model of prostate cancer
Scientific Reports, 2022 Prostate cancer is one of the few malignancies that includes vaccination as a treatment modality. Elements of an effective cancer vaccine should include the ability to elicit a Type I T-cell response and target multiple antigenic proteins expressed early
Denise L. Cecil +9 more
doaj +1 more source
Could widespread use of antiviral treatment curb the COVID-19 pandemic? A modeling study
BMC Infectious Diseases, 2022 Background Despite the development of safe and effective vaccines, effective treatments for COVID-19 disease are still urgently needed. Several antiviral drugs have shown to be effective in reducing progression of COVID-19 disease. Methods In the present
Laura Matrajt +4 more
doaj +1 more source
npj Breast Cancer, 2021 B cell responses to tumor antigens occur early in breast tumors and may identify immunogenic drivers of tumorigenesis. Sixty-two candidate antigens were identified prior to palpable tumor development in TgMMTV-neu and C3(1)Tag transgenic mouse mammary ...
Sasha E. Stanton +9 more
doaj +1 more source
Aging, cancer, and cancer vaccines [PDF]
Immunity & Ageing, 2012 AbstractWorld population has experienced continuous growth since 1400 A.D. Current projections show a continued increase - but a steady decline in the population growth rate - with the number expected to reach between 8 and 10.5 billion people within 40 years.
Marjorie R. Jenkins +9 more
openaire +3 more sources
Nature Communications, 2021 Most COVID-19 vaccines require two doses but a single dose provides partial protection, so it is unclear how best to prioritize vaccine distribution in the context of limited supply.
Laura Matrajt +6 more
doaj +1 more source